Bone Substitute Articles & Analysis
16 news found
The company, headquartered in Milan, Italy, currently has several assets under development, such as vascular graft, bone graft substitutes, rotator cuff repair, drug release. ...
ByKLISBio
KLISBio is targeting a variety of clinical indications, such as peripheral nerve injuries, peripheral vascular diseases, bone defects, tendon tears and situations where a sustained drug release is needed. ...
ByKLISBio
KLISBio is focused on healing and regenerating human body tissues by developing innovative solutions that solve prominent, unmet clinical needs through a silk-based multidisciplinary technology platform able to generate products and solutions for a variety of clinical indications, such as peripheral nerve injuries, peripheral vascular diseases, bone defects, tendon tears and ...
ByKLISBio
KLISBio is focused on developing innovative solutions that solve prominent unmet clinical needs through a silk-based multidisciplinary technology platform able to generate products and solutions for a variety of clinical indications, such as peripheral nerve injuries, peripheral vascular diseases, bone defects, tendon tears and situations where a sustained drug release is needed. ...
ByKLISBio
The company, headquartered in Milan, Italy, currently has several assets under development, such as vascular graft, bone graft substitutes, rotator cuff repair, drug release. ...
ByKLISBio
“KLISBio is focused on developing innovative solutions to tackle prominent unmet clinical needs through a silk-based multidisciplinary technology platform able to generate products and solutions for a variety of clinical indications, such as peripheral nerve injuries, peripheral vascular diseases, bone defects, tendon tears and situations where a sustained drug release is ...
ByKLISBio
He is credited with developing a wide variety of products for the global orthopaedics market spanning novel bone graft substitutes, biomimetic surfaces, and composite implants, and has overseen regulatory, quality and R&D functions. ...
KLISBio is focused on developing innovative solutions that solve prominent, unmet clinical needs through a silk-based multidisciplinary technology platform able to generate products and solutions for a variety of clinical indications, such as peripheral nerve injuries, peripheral vascular diseases, bone defects, tendon tears and situations where a sustained drug release is ...
ByKLISBio
KLISBio is focused on healing and regenerating human body tissues by developing innovative solutions that solve prominent, unmet clinical needs through a silk-based multidisciplinary technology platform able to generate products and solutions for a variety of clinical indications, such as peripheral nerve injuries, peripheral vascular diseases, bone defects, tendon tears and ...
ByKLISBio
Engineered silk materials provide a unique combination of outstanding biological and mechanical properties for a variety of clinical indications such as peripheral nerve injuries, peripheral vascular diseases, bone defects, tendon tears and situations where a sustained drug release is needed. ...
ByKLISBio
The application is specified for the indication osteomyelitis (bone infection) and can potentially result in an approval in Q1 of 2022. ...
CARLSBAD, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced it received simultaneous CE Mark certification for its Cranial Module and Percutaneous Spine Module for the 7D FLASH™ Navigation System. This achievement expands the ...
This agreement will further increase our potential reach across the US market”, said Emil Billbäck, CEO of BONESUPPORT. CERAMENT BONE VOID FILLER is an injectable, moldable and drillable synthetic bone graft substitute designed to help the bone heal in a natural way. ...
Currently, the standard treatment for chronic osteomyelitis is surgical debridement, long-term, high-dose administration of antibiotics, and – for larger defects – bone grafting which often requires a second surgical procedure to remove the non-resorbable bone graft. ...
GRAFTYS SA (“Graftys”), a global leader in resorbable bone cements, is proud to announce that as a fruitful result of 10 years’ partnership with its distributor - LAS Brasil, the milestone of 10,000 units of GRAFTYS® HBS sold in Brazil has been crossed during the third quarter of 2020. GRAFTYS® HBS is a calcium phosphate bone graft ...
ByGraftys
HCCP technology serves as the platform for MMI’s bone regeneration product, Osteo-P™ Bone Graft Substitute (BGS). ...